{
  "original": {
    "id": "unimed-open-innovation",
    "title": "Inventei plataforma aberta com LP SaaS que reduziu ciclo de inovacao em 68%",
    "title_pt": "Inventei plataforma aberta com LP SaaS que reduziu ciclo de inovacao em 68%",
    "title_en": "Invented open platform with SaaS LP that cut innovation cycle by 68%",
    "company": "Unimed",
    "period": "02/2022-12/2023",
    "isTopCase": false,
    "isGoodCase": true,
    "pt": {
      "s": "Eu encontrei o ecossistema de inovacao da Unimed travado por complexidade burocratica extrema: 47 projetos internos demoravam em media 21 meses para virar MVP, queimando R$ 2,1M cada um, e 63% eram cancelados sem tocar paciente algum. Doze startups parceiras tinham abandonado os pilotos porque levavam 140 dias para assinar NDA. Enquanto isso, 52 mil medicos cooperados reclamavam da burocracia e o NPS das solucoes digitais caiu de 55 para 28. Eu enxerguei que a dor nao era falta de ideias, mas excesso de camadas de aprovacao que matavam velocidade. Mantendo olhar externo, eu visitei oito cooperativas regionais em duas semanas e ouvi de gestores e pacientes que a dor real era a falta de solucoes simples para telemonitorar cronicos—e percebi que ninguem estava trazendo as praticas ageis do mercado fintech para dentro de casa.",
      "t": "Eu decidi ser owner de ponta a ponta e tracei a meta de inventar um hub aberto que gerasse MVP em seis meses, simplificando radicalmente o processo sem comprometer compliance ou qualidade clinica. Eu me comprometi a cortar o ciclo de aprovacao em 70%, entregar pelo menos tres solucoes com NPS acima de 60 ate o fim de 2023, e balancear inovacao com risco regulatorio atraves de mecanismos claros de governanca.",
      "a": "Primeiro, eu coletei dados de 1.260 horas de backlog e provei que 41% do tempo era gasto em comites desnecessarios. Eu decidi construir minha propria solucao—o \"Fast-Track Klin\"—em vez de contratar consultoria externa, porque precisava de algo customizado que acelerasse sem criar novos silos. Eu eliminei quatro camadas de aprovacao criando esse mecanismo onde eu, como sponsor, assinava contrato marco com startups em 10 dias e acionava um sandbox juridico. Segundo, eu mantive olhar externo constante: rodei 28 entrevistas com pacientes cronicos, analisei 180 mil mensagens da ouvidoria e priorizei solucoes de monitoramento remoto e adesao a terapias—trazendo essa escuta ativa de fora para dentro. Terceiro, eu enfrentei o trade-off classico entre inovacao e risco: o conselho financeiro temia exposure regulatorio, entao negociei um limite de R$ 15M com stop-loss por coorte e instalei OKRs vinculando retorno clinico e payback de 18 meses. Eu tambem organizei um \"clinical demo day\" onde cada startup apresentava resultados comigo e um medico patrocinador, convencendo lideres ceticos. Por fim, eu implementei a Plataforma de Inovacao aberta usando APIs FHIR e um repositório de dados que eu normalizei em quatro semanas, simplificando integracao de 140 dias para 10 dias.",
      "r": "Em dez meses eu lancei quatro solucoes priorizadas pela voz do paciente: telemonitoramento de insuficiencia cardiaca, adherence-as-a-service para oncologia, analytics de fila eletiva e triagem digital de saude mental. O ciclo medio caiu de 21 para 6,7 meses (68% de reducao), o custo de desenvolvimento baixou 44% e o NPS das solucoes passou para 64 em 90 dias. Gerei R$ 36M em economia projetada, reduzi readmissoes cardiacas em 19% e aumentei em 12 p.p. a adesao terapeutica em oncologia. O hub atraiu 96 startups, firmou 14 contratos ativos e ganhou selo ANS de inovacao responsavel.",
      "l": "Eu aprendi que simplicidade em inovacao corporativa so acontece quando alguem assume caneta unica para cortar burocracia, traz olhar externo constante (voz do cliente real) e balanceia risco com mecanismos claros. Construir solucao propria vs adaptar terceiros depende de quao especifico é o problema—no meu caso, a burocracia unica da Unimed exigia Fast-Track customizado. O mecanismo virou minha referencia para qualquer parceria fintech: contrato marco, voice of customer e sandbox legal que preserva velocidade sem comprometer compliance."
    },
    "en": {
      "s": "I found Unimed's innovation ecosystem paralyzed by extreme bureaucratic complexity: 47 internal projects took 21 months on average to reach MVP, burning R$ 2.1M each, and 63% were cancelled without touching any patient. Twelve partner startups had abandoned pilots because NDAs took 140 days to sign. Meanwhile 52 thousand cooperative physicians complained about bureaucracy and the digital solutions' NPS fell from 55 to 28. I saw the pain wasn't lack of ideas but excess approval layers killing speed. Keeping an external lens, I visited eight regional cooperatives in two weeks and heard from managers and patients that the true pain was the absence of simple tools to remotely monitor chronic conditions—and realized nobody was bringing agile fintech practices from outside in.",
      "t": "I chose to own end-to-end and set the goal to invent an open hub shipping MVPs in six months, radically simplifying the process without compromising compliance or clinical quality. I committed to shorten approval cycles by 70%, deliver at least three solutions with NPS above 60 by the end of 2023, and balance innovation with regulatory risk through clear governance mechanisms.",
      "a": "First, I collected data from 1,260 hours of backlog and proved 41% of time was wasted in unnecessary committees. I decided to build my own solution—the \"Fast-Track Klin\" mechanism—instead of hiring external consultancy, because I needed something custom that accelerated without creating new silos. I eliminated four approval layers by creating this mechanism where I, as sponsor, signed master agreements with startups in ten days and activated a legal sandbox. Second, I kept a constant external lens: I ran 28 interviews with chronic patients, analyzed 180 thousand ombudsman messages, and prioritized remote monitoring and therapy adherence solutions—bringing that active listening from outside in. Third, I faced the classic trade-off between innovation and risk: the finance board feared regulatory exposure, so I negotiated a R$ 15M cap with cohort stop-loss and installed OKRs linking clinical return and 18-month payback. I also organized a \"clinical demo day\" where each startup presented results alongside me and a physician sponsor, winning over skeptical leaders. Finally, I deployed the open innovation platform using FHIR APIs and a data repository I normalized within four weeks, simplifying integration from 140 days to 10 days.",
      "r": "In ten months I launched four patient-voice solutions: heart-failure telemonitoring, adherence-as-a-service for oncology, elective-surgery queue analytics, and digital mental-health triage. The average cycle dropped from 21 to 6.7 months (68% reduction), development cost fell 44%, and solution NPS climbed to 64 within 90 days. I generated R$ 36M in projected savings, reduced cardiac readmissions by 19%, and lifted oncology therapy adherence by 12 p.p. The hub attracted 96 startups, closed 14 active contracts, and earned the regulator's responsible-innovation seal.",
      "l": "I learned that simplicity in corporate innovation only happens when someone grabs a single pen to cut bureaucracy, brings constant external lens (real customer voice), and balances risk with clear mechanisms. Building your own solution vs adapting third-party depends on how specific the problem is—in my case, Unimed's unique bureaucracy required a custom Fast-Track. The mechanism became my blueprint for any fintech partnership: master agreement, customer voice, and a legal sandbox that preserves speed without compromising compliance."
    },
    "fups": [
      {
        "q": "Como voce priorizou as dores dos pacientes na escolha das startups?",
        "a": "Eu usei os 28 depth interviews e 180 mil registros da ouvidoria para criar um score de urgencia que pesava impacto clinico, frequencia e custo; as startups com score acima de 8 entraram na primeira onda.",
        "q_en": "How did you prioritize patient pains when selecting startups?",
        "a_en": "I combined the 28 depth interviews and 180 thousand ombudsman records into an urgency score weighing clinical impact, frequency, and cost; startups scoring above 8 joined wave one."
      },
      {
        "q": "Qual resistencia mais dura voce enfrentou e como venceu?",
        "a": "O conselho financeiro queria manter cinco aprovacoes sequenciais; eu levei analise mostrando 41% do tempo perdido e aceitei colocar stop-loss de R$ 15M com auditoria trimestral, assumindo responsabilidade pessoal pelas excecoes.",
        "q_en": "What was the toughest resistance and how did you win?",
        "a_en": "The finance board wanted five sequential approvals; I presented the 41% wasted-time analysis and accepted a R$ 15M stop-loss with quarterly audit, taking personal responsibility for exceptions."
      },
      {
        "q": "Como voce garantiu compliance regulatorio no sandbox?",
        "a": "Eu desenhei o sandbox com LGPD by design, criei contratos modulares revisados por mim e por um advogado dedicado e defini 22 controles obrigatorios monitorados via dashboard.",
        "q_en": "How did you guarantee regulatory compliance inside the sandbox?",
        "a_en": "I designed the sandbox LGPD-by-design, created modular contracts reviewed by me and a dedicated lawyer, and defined 22 mandatory controls monitored via dashboard."
      },
      {
        "q": "Como voce mediu o impacto financeiro das startups?",
        "a": "Eu cruzei dados de sinistralidade e call center, estimando economia de R$ 36M com base na reducao de readmissoes, menor uso de leitos e corte de consultas duplicadas.",
        "q_en": "How did you measure the financial impact from the startups?",
        "a_en": "I cross-referenced claims and call-center data, estimating R$ 36M in savings from fewer readmissions, reduced bed usage, and elimination of duplicate visits."
      },
      {
        "q": "Qual mecanismo voce deixou para evitar retrocesso burocratico?",
        "a": "Eu institucionalizei o comite Fast-Track com charter que me da voto qualificado, cadenciei reviews mensais e instalei scorecards publicos para todas as diretorias.",
        "q_en": "What mechanism did you leave to prevent bureaucratic relapse?",
        "a_en": "I institutionalized the Fast-Track committee with a charter granting me tie-breaking vote, scheduled monthly reviews, and published scorecards for every board."
      },
      {
        "q": "Como voce assegurou ratio EU:NOS elevado?",
        "a": "Eu assumi todas as negociacoes chave com startups, conduzi pessoalmente cada demo e registrei qual decisao eu tomei em ata, reforcando ownership individual.",
        "q_en": "How did you keep I:we ratio high?",
        "a_en": "I led every key negotiation with startups, personally ran each demo, and logged the decisions I made in the minutes to reinforce individual ownership."
      },
      {
        "q": "Que experimentos voce abortou e por que?",
        "a": "Eu encerrei duas provas de conceito em 30 dias porque nao atingiram 20% de adesao; comuniquei diretamente aos CEOs das startups e redirecionei budget para quem ja mostrava NPS acima de 60.",
        "q_en": "Which experiments did you kill and why?",
        "a_en": "I killed two proofs of concept within 30 days because they failed to reach 20% adoption; I told the startup CEOs directly and redirected budget to those already hitting NPS above 60."
      },
      {
        "q": "Como voce engajou os medicos cooperados?",
        "a": "Eu criei o clinical demo day com votacao, escolhi 15 lideres clinicos para co-patrocinar e garanti que cada caso de sucesso fosse compartilhado em boletins semanais.",
        "q_en": "How did you engage cooperative physicians?",
        "a_en": "I created the clinical demo day with voting, selected 15 clinical leaders as co-sponsors, and made sure each success case appeared in the weekly bulletins."
      },
      {
        "q": "Quais metricas voce monitora para sustentar o hub?",
        "a": "Eu acompanho time-to-MVP, NPS por solucao, payback, e um indice de risco regulatorio; mantenho gatilho que pausa onboarding se alguma startup exceder 10 incidentes de LGPD.",
        "q_en": "Which metrics do you track to sustain the hub?",
        "a_en": "I track time-to-MVP, solution NPS, payback, and a regulatory-risk index; I keep a trigger that pauses onboarding if any startup exceeds ten LGPD incidents."
      },
      {
        "q": "Como esse mecanismo escala para pagamentos?",
        "a": "Eu aplico o Fast-Track Klin em parcerias com fintechs: contrato marco, base de clientes priorizada por dor e sandbox legal que me permite testar compliance rapidamente.",
        "q_en": "How does this mechanism scale into payments?",
        "a_en": "I apply the Fast-Track Klin approach to fintech partnerships: master agreement, customer-pain based prioritization, and a legal sandbox that lets me validate compliance fast."
      }
    ],
    "__file": "src\\data\\invent_and_simplify\\invent_and_simplify_case4.js",
    "lp_id": "invent_and_simplify",
    "__load_warnings": []
  },
  "mutated": {
    "id": "unimed-open-innovation",
    "title": "Inventei plataforma aberta com LP SaaS que reduziu ciclo de inovacao em 68%",
    "title_pt": "Inventei plataforma aberta com LP SaaS que reduziu ciclo de inovacao em 68%",
    "title_en": "Invented open platform with SaaS LP that cut innovation cycle by 68%",
    "company": "Unimed",
    "period": "02/2022-12/2023",
    "isTopCase": false,
    "isGoodCase": true,
    "pt": {
      "s": "O desafio começou quando eu encontrei o ecossistema de inovacao da Unimed travado por complexidade burocratica extrema: 47 projetos internos demoravam em media 21 meses para virar MVP, queimando R$ 2,1M cada um, e 63% eram cancelados sem tocar paciente algum. Doze startups parceiras tinham abandonado os pilotos porque levavam 140 dias para assinar NDA. Enquanto isso, 52 mil medicos cooperados reclamavam da burocracia e o NPS das solucoes digitais caiu de 55 para 28. Eu enxerguei que a dor nao era falta de ideias, mas excesso de camadas de aprovacao que matavam velocidade. Mantendo olhar externo, eu visitei oito cooperativas regionais em duas semanas e ouvi de gestores e pacientes que a dor real era a falta de solucoes simples para telemonitorar cronicos—e percebi que ninguem estava trazendo as praticas ageis do mercado fintech para dentro de casa.",
      "t": "Eu decidi ser owner de ponta a ponta e tracei a meta de inventar um hub aberto que gerasse MVP em seis meses, simplificando radicalmente o processo sem comprometer compliance ou qualidade clinica. Eu me comprometi a cortar o ciclo de aprovacao em 70%, entregar pelo menos tres solucoes com NPS acima de 60 ate o fim de 2023, e balancear inovacao com risco regulatorio atraves de mecanismos claros de governanca.",
      "a": "Primeiro, eu coletei dados de 1.260 horas de backlog e provei que 41% do tempo era gasto em comites desnecessarios. Eu decidi construir minha propria solucao—o \"Fast-Track Klin\"—em vez de contratar consultoria externa, porque precisava de algo customizado que acelerasse sem criar novos silos. Eu eliminei quatro camadas de aprovacao criando esse mecanismo onde eu, como sponsor, assinava contrato marco com startups em 10 dias e acionava um sandbox juridico. Segundo, eu mantive olhar externo constante: rodei 28 entrevistas com pacientes cronicos, analisei 180 mil mensagens da ouvidoria e priorizei solucoes de monitoramento remoto e adesao a terapias—trazendo essa escuta ativa de fora para dentro. Terceiro, eu enfrentei o trade-off classico entre inovacao e risco: o conselho financeiro temia exposure regulatorio, entao negociei um limite de R$ 15M com stop-loss por coorte e instalei OKRs vinculando retorno clinico e payback de 18 meses. Eu tambem organizei um \"clinical demo day\" onde cada startup apresentava resultados comigo e um medico patrocinador, convencendo lideres ceticos. Por fim, eu implementei a Plataforma de Inovacao aberta usando APIs FHIR e um repositório de dados que eu normalizei em quatro semanas, simplificando integracao de 140 dias para 10 dias.",
      "r": "Em dez meses eu lancei quatro solucoes priorizadas pela voz do paciente: telemonitoramento de insuficiencia cardiaca, adherence-as-a-service para oncologia, analytics de fila eletiva e triagem digital de saude mental. O ciclo medio caiu de 21 para 6,7 meses (68% de reducao), o custo de desenvolvimento baixou 44% e o NPS das solucoes passou para 64 em 90 dias. Gerei R$ 36M em economia projetada, reduzi readmissoes cardiacas em 19% e aumentei em 12 p.p. a adesao terapeutica em oncologia. O hub atraiu 96 startups, firmou 14 contratos ativos e ganhou selo ANS de inovacao responsavel.",
      "l": "Eu aprendi que simplicidade em inovacao corporativa so acontece quando alguem assume caneta unica para cortar burocracia, traz olhar externo constante (voz do cliente real) e balanceia risco com mecanismos claros. Construir solucao propria vs adaptar terceiros depende de quao especifico é o problema—no meu caso, a burocracia unica da Unimed exigia Fast-Track customizado. O mecanismo virou minha referencia para qualquer parceria fintech: contrato marco, voice of customer e sandbox legal que preserva velocidade sem comprometer compliance."
    },
    "en": {
      "s": "The challenge began when i found Unimed's innovation ecosystem paralyzed by extreme bureaucratic complexity: 47 internal projects took 21 months on average to reach MVP, burning R$ 2.1M each, and 63% were cancelled without touching any patient. Twelve partner startups had abandoned pilots because NDAs took 140 days to sign. Meanwhile 52 thousand cooperative physicians complained about bureaucracy and the digital solutions' NPS fell from 55 to 28. I saw the pain wasn't lack of ideas but excess approval layers killing speed. Keeping an external lens, I visited eight regional cooperatives in two weeks and heard from managers and patients that the true pain was the absence of simple tools to remotely monitor chronic conditions—and realized nobody was bringing agile fintech practices from outside in.",
      "t": "I chose to own end-to-end and set the goal to invent an open hub shipping MVPs in six months, radically simplifying the process without compromising compliance or clinical quality. I committed to shorten approval cycles by 70%, deliver at least three solutions with NPS above 60 by the end of 2023, and balance innovation with regulatory risk through clear governance mechanisms.",
      "a": "First, I collected data from 1,260 hours of backlog and proved 41% of time was wasted in unnecessary committees. I decided to build my own solution—the \"Fast-Track Klin\" mechanism—instead of hiring external consultancy, because I needed something custom that accelerated without creating new silos. I eliminated four approval layers by creating this mechanism where I, as sponsor, signed master agreements with startups in ten days and activated a legal sandbox. Second, I kept a constant external lens: I ran 28 interviews with chronic patients, analyzed 180 thousand ombudsman messages, and prioritized remote monitoring and therapy adherence solutions—bringing that active listening from outside in. Third, I faced the classic trade-off between innovation and risk: the finance board feared regulatory exposure, so I negotiated a R$ 15M cap with cohort stop-loss and installed OKRs linking clinical return and 18-month payback. I also organized a \"clinical demo day\" where each startup presented results alongside me and a physician sponsor, winning over skeptical leaders. Finally, I deployed the open innovation platform using FHIR APIs and a data repository I normalized within four weeks, simplifying integration from 140 days to 10 days.",
      "r": "In ten months I launched four patient-voice solutions: heart-failure telemonitoring, adherence-as-a-service for oncology, elective-surgery queue analytics, and digital mental-health triage. The average cycle dropped from 21 to 6.7 months (68% reduction), development cost fell 44%, and solution NPS climbed to 64 within 90 days. I generated R$ 36M in projected savings, reduced cardiac readmissions by 19%, and lifted oncology therapy adherence by 12 p.p. The hub attracted 96 startups, closed 14 active contracts, and earned the regulator's responsible-innovation seal.",
      "l": "I learned that simplicity in corporate innovation only happens when someone grabs a single pen to cut bureaucracy, brings constant external lens (real customer voice), and balances risk with clear mechanisms. Building your own solution vs adapting third-party depends on how specific the problem is—in my case, Unimed's unique bureaucracy required a custom Fast-Track. The mechanism became my blueprint for any fintech partnership: master agreement, customer voice, and a legal sandbox that preserves speed without compromising compliance."
    },
    "fups": [
      {
        "q": "Como voce priorizou as dores dos pacientes na escolha das startups?",
        "a": "Eu usei os 28 depth interviews e 180 mil registros da ouvidoria para criar um score de urgencia que pesava impacto clinico, frequencia e custo; as startups com score acima de 8 entraram na primeira onda.",
        "q_en": "How did you prioritize patient pains when selecting startups?",
        "a_en": "I combined the 28 depth interviews and 180 thousand ombudsman records into an urgency score weighing clinical impact, frequency, and cost; startups scoring above 8 joined wave one."
      },
      {
        "q": "Qual resistencia mais dura voce enfrentou e como venceu?",
        "a": "O conselho financeiro queria manter cinco aprovacoes sequenciais; eu levei analise mostrando 41% do tempo perdido e aceitei colocar stop-loss de R$ 15M com auditoria trimestral, assumindo responsabilidade pessoal pelas excecoes.",
        "q_en": "What was the toughest resistance and how did you win?",
        "a_en": "The finance board wanted five sequential approvals; I presented the 41% wasted-time analysis and accepted a R$ 15M stop-loss with quarterly audit, taking personal responsibility for exceptions."
      },
      {
        "q": "Como voce garantiu compliance regulatorio no sandbox?",
        "a": "Eu desenhei o sandbox com LGPD by design, criei contratos modulares revisados por mim e por um advogado dedicado e defini 22 controles obrigatorios monitorados via dashboard.",
        "q_en": "How did you guarantee regulatory compliance inside the sandbox?",
        "a_en": "I designed the sandbox LGPD-by-design, created modular contracts reviewed by me and a dedicated lawyer, and defined 22 mandatory controls monitored via dashboard."
      },
      {
        "q": "Como voce mediu o impacto financeiro das startups?",
        "a": "Eu cruzei dados de sinistralidade e call center, estimando economia de R$ 36M com base na reducao de readmissoes, menor uso de leitos e corte de consultas duplicadas.",
        "q_en": "How did you measure the financial impact from the startups?",
        "a_en": "I cross-referenced claims and call-center data, estimating R$ 36M in savings from fewer readmissions, reduced bed usage, and elimination of duplicate visits."
      },
      {
        "q": "Qual mecanismo voce deixou para evitar retrocesso burocratico?",
        "a": "Eu institucionalizei o comite Fast-Track com charter que me da voto qualificado, cadenciei reviews mensais e instalei scorecards publicos para todas as diretorias.",
        "q_en": "What mechanism did you leave to prevent bureaucratic relapse?",
        "a_en": "I institutionalized the Fast-Track committee with a charter granting me tie-breaking vote, scheduled monthly reviews, and published scorecards for every board."
      },
      {
        "q": "Como voce assegurou ratio EU:NOS elevado?",
        "a": "Eu assumi todas as negociacoes chave com startups, conduzi pessoalmente cada demo e registrei qual decisao eu tomei em ata, reforcando ownership individual.",
        "q_en": "How did you keep I:we ratio high?",
        "a_en": "I led every key negotiation with startups, personally ran each demo, and logged the decisions I made in the minutes to reinforce individual ownership."
      },
      {
        "q": "Que experimentos voce abortou e por que?",
        "a": "Eu encerrei duas provas de conceito em 30 dias porque nao atingiram 20% de adesao; comuniquei diretamente aos CEOs das startups e redirecionei budget para quem ja mostrava NPS acima de 60.",
        "q_en": "Which experiments did you kill and why?",
        "a_en": "I killed two proofs of concept within 30 days because they failed to reach 20% adoption; I told the startup CEOs directly and redirected budget to those already hitting NPS above 60."
      },
      {
        "q": "Como voce engajou os medicos cooperados?",
        "a": "Eu criei o clinical demo day com votacao, escolhi 15 lideres clinicos para co-patrocinar e garanti que cada caso de sucesso fosse compartilhado em boletins semanais.",
        "q_en": "How did you engage cooperative physicians?",
        "a_en": "I created the clinical demo day with voting, selected 15 clinical leaders as co-sponsors, and made sure each success case appeared in the weekly bulletins."
      },
      {
        "q": "Quais metricas voce monitora para sustentar o hub?",
        "a": "Eu acompanho time-to-MVP, NPS por solucao, payback, e um indice de risco regulatorio; mantenho gatilho que pausa onboarding se alguma startup exceder 10 incidentes de LGPD.",
        "q_en": "Which metrics do you track to sustain the hub?",
        "a_en": "I track time-to-MVP, solution NPS, payback, and a regulatory-risk index; I keep a trigger that pauses onboarding if any startup exceeds ten LGPD incidents."
      },
      {
        "q": "Como esse mecanismo escala para pagamentos?",
        "a": "Eu aplico o Fast-Track Klin em parcerias com fintechs: contrato marco, base de clientes priorizada por dor e sandbox legal que me permite testar compliance rapidamente.",
        "q_en": "How does this mechanism scale into payments?",
        "a_en": "I apply the Fast-Track Klin approach to fintech partnerships: master agreement, customer-pain based prioritization, and a legal sandbox that lets me validate compliance fast."
      }
    ],
    "__file": "src\\data\\invent_and_simplify\\invent_and_simplify_case4.js",
    "lp_id": "invent_and_simplify",
    "__load_warnings": [],
    "__scorecard": {
      "score": 85,
      "status": "Ready",
      "positives": [
        "Métricas robustas (26)",
        "Ratio EU:NÓS saudável (36.0:1)"
      ],
      "warnings": [
        "Hook inicial fraco (sem urgência ou stakes claros)",
        "Faltam transições narrativas entre seções STARL"
      ],
      "dealbreakers": [],
      "suggestions": [
        {
          "severity": "suggestion",
          "topic": "hook",
          "message": "[pt] Hook (S) reescrito para maior impacto.",
          "action": "Validar se o novo hook captura a urgência e os stakes do caso."
        },
        {
          "severity": "suggestion",
          "topic": "hook",
          "message": "[en] Hook (S) reescrito para maior impacto.",
          "action": "Validar se o novo hook captura a urgência e os stakes do caso."
        },
        {
          "severity": "warning",
          "topic": "warning",
          "message": "Hook inicial fraco (sem urgência ou stakes claros)",
          "action": "Reescrever abertura da Situa��o com tens�o executiva: risco, meta agressiva, impacto financeiro."
        },
        {
          "severity": "warning",
          "topic": "warning",
          "message": "Faltam transições narrativas entre seções STARL",
          "action": "Refinar narrativa conforme alerta."
        }
      ],
      "lint": {
        "ok": true,
        "issues": [],
        "warnings": []
      },
      "heur": {
        "score": 85,
        "status": "Ready",
        "dealbreakers": [],
        "warnings": [
          "Hook inicial fraco (sem urgência ou stakes claros)",
          "Faltam transições narrativas entre seções STARL"
        ],
        "positives": [
          "Métricas robustas (26)",
          "Ratio EU:NÓS saudável (36.0:1)"
        ],
        "breakdown": {
          "narrative": 6,
          "metrics": 19,
          "lpContent": 20,
          "amazonAspects": 15,
          "contribution": 10,
          "structure": 10
        },
        "details": {
          "metrics": {
            "count": 26,
            "hasFinancial": true,
            "hasCustomer": true,
            "hasOperational": false
          },
          "contribution": {
            "ratio": 36,
            "eu": 36,
            "nos": 0
          },
          "amazonAspects": {
            "customerSignals": 10,
            "mechanismSignals": 3,
            "conflictSignals": 2
          },
          "lpContent": {
            "strongCount": 12,
            "mediumCount": 0
          }
        }
      }
    }
  }
}